Current status and future outlook for patient-derived cancer models from a rare cancer research perspective.

ABSTRACT: Rare cancers are a group of approximately 200 malignancies with extremely low incidences and with a wide variety of genotypes and phenotypes. Collectively, they are more common than any single malignancy. However, given the small numbers of individuals diagnosed with rare cancers, it is difficult to design clinical trials with sufficient patient numbers. Therefore, few effective anticancer drugs have been developed, and evidence-based medicine is not always feasible for rare cancers. Consequently, their clinical outcomes are generally poorer. Cancer research requires adequate models that faithfully recapitulate molecular features and reproduce treatment responses of the original tumors. Such models allow us to focus on more efficacious drugs in the clinical studies. For rare cancers, patie

SUBMITTER: Kondo T 

PROVIDER: S-EPMC7935796 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature